Regulators question industry's own-branding paper:
This article was originally published in Clinica
There has been a cautious reception among some Competent Authorities to the industry position paper on procedures for companies marketing under their own name CE-marked medical devices made by third parties. Some aspects of the text, written by the European Medical Industries Group, the umbrella organisation representing European medical device industry associations, need clarification, say the regulators.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.